Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival

被引:69
作者
Samson, Pamela
Crabtree, Traves
Broderick, Stephen
Kreisel, Daniel
Krupnick, A. Sasha
Patterson, G. Alexander
Meyers, Bryan
Puri, Varun [1 ]
机构
[1] Washington Univ, Sch Med, Div Cardiothorac Surg, 660 S Euclid Ave,Campus Box 8234, St Louis, MO 63110 USA
基金
美国国家卫生研究院;
关键词
SUBLOBAR RESECTION; OPEN LOBECTOMY; THORACOSCOPIC LOBECTOMY; MATCHED ANALYSIS; NUMBER; SEGMENTECTOMY; DIAGNOSIS; OUTCOMES; SURGERY; TERM;
D O I
10.1016/j.athoracsur.2016.07.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. National organizations have recommended quality measures for operations in early-stage non-small cell lung cancer (NSCLC). The outcomes of adherence to these guidelines are unknown. Methods. Information about patients who underwent an operation for clinical stage I NSCLC was abstracted from the National Cancer Database. After reviewing current guidelines, the following quality measures were selected: anatomic resection, operation within 8 weeks of diagnosis, achievement of negative surgical margins, and sampling of 10 or more lymph nodes. Multivariate models identified variables independently associated with receiving quality measures and a Cox model created to evaluate overall survival. Results. Between 2004 and 2013, 133,026 of 133,366 (99.7%), 126,598 of 133,366 (94.9%), 91,472 of 133,366 (68.6%), and 30,041 of 133,366 (22.5%) patients met one, two, three, or four measures. Income of at least $38,000/year (odds ratio [OR] 1.20, 95% CI: 1.15 to 1.24), insurance type (private insurance: OR 1.22, 95% CI: 1.09 to 1.36; Medicare: OR 1.16, 95% CI: 1.04 to 1.30), centers with at least 38 cases/year (OR 1.18, 95% CI: 1.14 to 1.22), academic institutions (OR 1.31, 95% CI: 1.27 to 1.35), and clinical stage IB patients (OR 1.50, 95% CI: 1.40 to 1.60) were more likely to meet all four measures; whereas increasing age (OR 0.99, 95% CI: 0.99 to 0.99), women (OR 0.93, 95% CI: 0.91 to 0.96), non-Caucasian race (OR 0.83, 95% CI: 0.79 to 0.87), and increasing Charlson/Deyo comorbidity score (1: OR 0.90, 95% CI: 0.87 to 0.93; >= 2: OR 0.82, 95% CI: 0.79 to 0.86) were associated with lower likelihood. Pathologic upstaging (hazard ratio [HR] 1.84, 95% CI: 1.78 to 1.89) and meeting all four measures (HR 0.39, 95% CI: 0.31 to 0.48) were most powerfully associated with overall survival. Conclusions. National adherence to quality measures in stage I NSCLC resection is suboptimal. Guideline compliance is strongly associated with survival, and vigorous efforts should be instituted by national societies to improve adherence. (C) 2017 by The Society of Thoracic Surgeons
引用
收藏
页码:303 / 311
页数:9
相关论文
共 26 条
  • [1] Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules
    Altorki, Nasser K.
    Yip, Rowena
    Hanaoka, Takaomi
    Bauer, Thomas
    Aye, Ralph
    Kohman, Leslie
    Sheppard, Barry
    Thurer, Richard
    Andaz, Shahriyour
    Smith, Michael
    Mayfield, William
    Grannis, Fred
    Korst, Robert
    Pass, Harvey
    Straznicka, Michaela
    Flores, Raja
    Henschke, Claudia I.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2014, 147 (02) : 754 - 762
  • [2] American College of Surgeons Commission on Cancer, CANC PROGR PRACT PRO
  • [3] [Anonymous], 2016, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer
  • [4] Gaps in Guideline-Concordant Use of Diagnostic Tests Among Lung Cancer Patients
    Flanagan, Meghan R.
    Varghese, Thomas K.
    Backhus, Leah M.
    Wood, Douglas E.
    Mulligan, Michael S.
    Cheng, Aaron M.
    Flum, David R.
    Farjah, Farhood
    [J]. ANNALS OF THORACIC SURGERY, 2015, 100 (06) : 2006 - 2012
  • [5] Completing the Audit Cycle Improves Surgical Standards in Lung Cancer Why Do Some Patients Still Not Receive the Best Care?
    Hagan, Marissa E.
    Williams, Sophie T.
    Socci, Laura
    Malik, Munib
    Internullo, Eveline
    Martin-Ucar, Antonio Eduardo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (06) : 779 - 782
  • [6] Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery
    Hancock, Jacquelyn G.
    Rosen, Joshua E.
    Antonicelli, Alberto
    Moreno, Amy
    Kim, Anthony W.
    Detterbeck, Frank C.
    Boffa, Daniel J.
    [J]. ANNALS OF THORACIC SURGERY, 2015, 99 (02) : 406 - 413
  • [7] Treatment of Stage I and II Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Howington, John A.
    Blum, Matthew G.
    Chang, Andrew C.
    Balekian, Alex A.
    Murthy, Sudish C.
    [J]. CHEST, 2013, 143 (05) : E278 - E313
  • [8] Survival After Community Diagnosis of Early-stage Non-small Cell Lung Cancer
    Kanarek, Norma F.
    Hooker, Craig M.
    Mathieu, Luckson
    Tsai, Hua-Ling
    Rudin, Charles M.
    Herman, James G.
    Brock, Malcolm V.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2014, 127 (05) : 443 - 449
  • [9] Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer An Analysis from the National Cancer Data Base
    Khullar, Onkar V.
    Liu, Yuan
    Gillespie, Theresa
    Higgins, Kristin A.
    Ramalingam, Suresh
    Lipscomb, Joseph
    Fernandez, Felix G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (11) : 1625 - 1633
  • [10] A National Study of Nodal Upstaging After Thoracoscopic Versus Open Lobectomy for Clinical Stage I Lung Cancer
    Licht, Peter B.
    Jorgensen, Ole Dan
    Ladegaard, Lars
    Jakobsen, Erik
    [J]. ANNALS OF THORACIC SURGERY, 2013, 96 (03) : 943 - 950